psalexa
logo

Contract Research Organization Market

Global Contract Research Organization (CRO) Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10543
Available Format:
Category : Healthcare

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Service Type

1.3.2. Market Segmentation by Therapeutic Area

1.3.3. Market Segmentation by End User

1.3.4. Market Segmentation by Geography

1.3.5. Analysis Period

1.3.6. Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By region

2.2.1.2. By industry participants

2.2.1.3. By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Service Type

4.1.1.1. Early-phase development services

4.1.1.1.1. Discovery studies

4.1.1.1.2. Chemistry, manufacturing & control (CMC)

4.1.1.1.3. Preclinical services

4.1.1.2. Clinical research services

4.1.1.2.1. Phase I clinical research services

4.1.1.2.2. Phase II clinical research services

4.1.1.2.3. Phase III clinical research services

4.1.1.2.4. Phase IV clinical research services

4.1.1.3. Laboratory services

4.1.1.3.1. Bioanalytical testing services

4.1.1.3.2. Analytical testing services

4.1.1.4. Consulting service

4.1.2. Overview by Therapeutic Area

4.1.2.1. Oncology

4.1.2.2. Cardiovascular

4.1.2.3. Central nervous system (CNS)

4.1.2.4. Diabetes

4.1.2.5. Respiratory

4.1.2.6. Others

4.1.3. Overview by End User

4.1.3.1. Pharmaceutical and biopharmaceutical companies

4.1.3.2. Medical device companies

4.1.3.3. Others

4.2. Market Dynamics

4.2.1. Trends

4.2.2. Drivers

4.2.2.1. Impact analysis of drivers on market forecast

4.2.3. Restraints

4.2.3.1. Impact analysis of restraints on market forecast

4.2.4. Opportunities

4.3. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Service Type

5.1. Early-Phase Development Services

5.1.1. Discovery Studies

5.1.2. Chemistry, Manufacturing & Control (CMC)

5.1.3. Preclinical Services

5.2. Clinical Research Services

5.2.1. Phase I Clinical Research Services

5.2.2. Phase II Clinical Research Services

5.2.3. Phase III Clinical Research Services

5.2.4. Phase IV Clinical Research Services

5.3. Laboratory Services

5.3.1. Bioanalytical Testing Services

5.3.2. Analytical Testing Services

5.4. Consulting Service

Chapter 6. Market Size and Forecast by Therapeutic Area

6.1. Oncology

6.2. Cardiovascular

6.3. Central nervous system (CNS)

6.4. Diabetes

6.5. Respiratory

6.6. Others

Chapter 7. Market Size and Forecast by End User

7.1. Pharmaceutical and Biopharmaceutical Companies

7.2. Medical Device Companies

7.3. Others

Chapter 8. Market Size and Forecast by Geography

8.1. North America Contract Research Organization Market

8.1.1. By Type

8.1.2. By Therapeutic Area

8.1.3. By End User

8.1.4. By Country-The U.S, and Canada

8.2. Europe Contract Research Organization Market

8.2.1. By Type

8.2.2. By Therapeutic Area

8.2.3. By End User

8.2.4. By Country –Germany, France, U.K and Rest of Europe

8.3. Asia-Pacific Contract Research Organization Market

8.3.1. By Type

8.3.2. By Therapeutic Area

8.3.3. By End User

8.3.4. By Country -China, Japan, India, Australia and Rest of Asia-Pacific

8.4. Latin America Contract Research Organization Market

8.4.1. By Type

8.4.2. By Therapeutic Area

8.4.3. By End User

8.4.4. By Country – Brazil and Rest of Latin America

8.5. Middle East & Africa Contract Research Organization Market

8.5.1. By Type

8.5.2. By Therapeutic Area

8.5.3. By End User

Chapter 9. Competitive Landscape

9.1. Competitive Analysis of Key Players

9.2. Global Strategic Developments

Chapter 10. Company Profiles

10.1. Laboratory Corporation of America Holdings

10.1.1. Business Overview

10.1.2. Product and Service Offerings

10.1.3. Key Financial Summary

10.1.4. Strategic Growth Plan

10.2. Quintiles IMS Holdings, Inc.

10.2.1. Business Overview

10.2.2. Product and Service Offerings

10.2.3. Key Financial Summary

10.2.4. Strategic Growth Plan

10.3. PAREXEL International Corporation

10.3.1. Business Overview

10.3.2. Product and Service Offerings

10.3.3. Key Financial Summary

10.3.4. Strategic Growth Plan

10.4. Charles River Laboratories, Inc.

10.4.1. Business Overview

10.4.2. Product and Service Offerings

10.4.3. Key Financial Summary

10.4.4. Strategic Growth Plan

10.5. Pharmaceutical Product Development, LLC

10.5.1. Business Overview

10.5.2. Product and Service Offerings

10.5.3. Key Financial Summary

10.5.4. Strategic Growth Plan

10.6. ICON plc

10.6.1. Business Overview

10.6.2. Product and Service Offerings

10.6.3. Key Financial Summary

10.6.4. Strategic Growth Plan

10.7. PRA Health Sciences

10.7.1. Business Overview

10.7.2. Product and Service Offerings

10.7.3. Key Financial Summary

10.7.4. Strategic Growth Plan

10.8. inVentiv Health, Inc.

10.8.1. Business Overview

10.8.2. Product and Service Offerings

10.8.3. Key Financial Summary

10.8.4. Strategic Growth Plan

 *Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.

Chapter 11. Appendix

11.1. Abbreviations

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry